Valneva SE (VLA.PA)

5,52 -0,01 (-0,11%) Alla chiusura: 05:35PM CEST

Valneva SE

6 rue Alain Bombard
Saint-Herblain 44800
France
33 2 28 07 37 10
https://valneva.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 700

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Thomas Lingelbach	Chairman of the Management Board, Pres & CEO	783,68k	N/D	1963
Mr. Peter Buhler	CFO & Management Board Member	519,98k	N/D	1971
Mr. Franck Grimaud MBA	Director Gen., Chief Bus. Officer & Member of Management Board	389,29k	N/D	1967
Mr. Frederic Jacotot	VP of Legal & IP, Gen. Counsel, Corp. Sec. and Member of Management Board	298,48k	N/D	1965
Dr. Juan-Carlos Jaramillo M.D.	Chief Medical Officer & Member of the Management Board	472,53k	N/D	1972
Ms. Dipal Patel	Chief Commercial Officer & Member of Management Board	759,39k	N/D	1974
Mr. Perry Celentano	Interim Chief Operating Officer	N/D	N/D	N/D
Mr. Joshua Drumm Ph.D.	VP of Investor Relations	N/D	N/D	N/D
Ms. Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations	N/D	N/D	N/D
Mr. Gerald Strohmaier	VP of Human Resource	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.

Governance aziendale

L'ISS Governance QualityScore di Valneva SE al 1 settembre 2023 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 4; diritti degli azionisti: 6; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.